Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion.
about
Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent "Mycophenolate Mofetil" in rats.Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantationMycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient miceMycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies.Enteric-coated mycophenolate sodium.Review of the immunosuppressant enteric-coated mycophenolate sodium.Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.Mycophenolates in transplantation.A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids.Therapeutic monitoring of immunosuppressant drugs. Where are we?Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?Time-dependent clearance of mycophenolic acid in renal transplant recipientsNo relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.Free mycophenolic acid determination in human plasma ultrafiltrate by a validated liquid chromatography-tandem mass spectrometry method.Individualization of mycophenolate mofetil dose in renal transplant recipients.Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?A limited sampling strategy for tacrolimus in renal transplant patientsInosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review.Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.State of the art in therapeutic drug monitoring.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.To TDM or not to TDM in lupus nephritis patients treated with MMF?Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.Correlation between pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients.Enteric-coated mycophenolate sodium - current and future use in transplant patients.What is the intrapatient variability of mycophenolic acid trough levels?Mycophenolic acid area under the curve recovery time following rifampicin withdrawal.Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients.Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction.
P2860
Q33370034-C82C7F1F-A187-4621-BAF5-66551BF1BB59Q33434301-72491728-ED29-4BC8-BC2C-1303280A5AA7Q33984216-AF0F3515-FFE6-40D5-9EA5-626B1A4D966AQ34180482-DE12E8D8-2B4A-48E8-90AF-906E7F780393Q34611858-26C4D7CF-F1B6-4F71-90B6-78FEC3AB1533Q34728886-0BA01306-C621-416C-8529-9CA06A208069Q35129548-B459A34B-924C-43C3-A316-0AACA80FA638Q35562618-40E384DA-F8D5-4DD0-AEEC-D3B36905FB9DQ35784063-9D9A17E7-AA48-4814-95CE-1E4C31AFC02FQ35825497-DFA1AD42-12CC-4ABE-9C3C-D4204A5ACD13Q35827807-4EDE8BB2-EB0B-477D-B8F9-8106B8539876Q35848175-F80C4053-AFBD-4496-98AD-C476D5D4204CQ35877512-AD979510-3106-4DD1-BB0A-84BD0CE385A2Q35893989-35768476-E1A1-410C-83B3-537D335E4E6CQ35970335-5B97EFD1-ED0D-4420-8FFE-2983332C9E64Q35980234-BF3C072A-F821-498F-8CDB-2F0FCEF369D4Q36024478-5A0594CC-70C3-4FC7-B3CB-BCC7B8DDA935Q36243648-26CEEB40-23AE-4FE9-BDD3-52DDAD5A9600Q36314080-190CA5F7-71DD-45FD-839A-91BC2A16725BQ36407345-54137861-9714-40E0-87CE-03BCA4DD9647Q36482172-DD4EA5C4-FC5A-42CE-AF89-A92554711335Q36788423-389B55A9-D767-49AB-B1ED-389AF1EA50E0Q36922261-1013F641-CC24-47DB-91C4-0F3787381B53Q37161962-1A6C54D4-D6B2-4072-9F90-DA533005CA3AQ37423423-0AFFFA3A-85E2-43D2-9D3F-7F6DEC80ABDBQ37441778-C24E53DE-3343-4AF4-9DC3-5DBB13DDF08FQ37581617-9B9366F3-A68F-400E-8BDA-67DF3A4246D4Q37582505-EB4A980B-44E8-4621-865F-E0ADD9715A05Q37699413-D916FD07-C24D-49CF-A0CB-4D1389654B3DQ38010596-3D58468A-F90C-4EBC-9F8E-9CF0235BBDB8Q38210402-1AA9F8FA-D8D2-45B3-89F8-413CF3FDA607Q38223136-6628C3C0-EBB7-4038-8D04-80168C87D64CQ38610665-A4B9DCAC-627F-4A92-B04B-B5CB6812A526Q39729251-C109C5CB-797C-46EE-9211-B4299EB1BC7FQ40409829-13E8A0E7-6360-4AB3-AC63-491061F12BFEQ40707992-64319F83-6C07-4C68-8A3E-FDB41CDE6F15Q40810653-00A8ECD9-537C-41C7-8212-17DADF6DE6D3Q42597049-8FB436A4-BBBE-4104-903C-CAAC5CA02E4EQ43921775-7FE2F38B-3907-4403-A3DD-D4FAEA2FED82Q44412745-46FB29B8-3CA4-44D0-B942-21FA0EB150C6
P2860
Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Current issues in therapeutic ...... rt of a roundtable discussion.
@ast
Current issues in therapeutic ...... rt of a roundtable discussion.
@en
Current issues in therapeutic ...... rt of a roundtable discussion.
@nl
type
label
Current issues in therapeutic ...... rt of a roundtable discussion.
@ast
Current issues in therapeutic ...... rt of a roundtable discussion.
@en
Current issues in therapeutic ...... rt of a roundtable discussion.
@nl
prefLabel
Current issues in therapeutic ...... rt of a roundtable discussion.
@ast
Current issues in therapeutic ...... rt of a roundtable discussion.
@en
Current issues in therapeutic ...... rt of a roundtable discussion.
@nl
P2093
P1476
Current issues in therapeutic ...... rt of a roundtable discussion.
@en
P2093
P304
P356
10.1097/00007691-200108000-00001
P577
2001-08-01T00:00:00Z